Stephens & Co. Reiterates Equal-Weight on Amedisys, Maintains $103 Price Target
Stephens & Co. analyst Scott Fidel reiterates Amedisys (NASDAQ:AMED) with a Equal-Weight and maintains $103 price target.
RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target
RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.
RBC Capital Reiterates Sector Perform on Paysafe, Maintains $36 Price Target
RBC Capital analyst Daniel Perlin reiterates Paysafe (NYSE:PSFE) with a Sector Perform and maintains $36 price target.
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics – 1-for-18 Reverse Stock Split
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy, 1-for-18 reverse stock split.
RBC Capital Reiterates Sector Perform on BioCryst Pharma, Maintains $10 Price Target
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Sector Perform and maintains $10 price target.
JMP Securities Reiterates Market Outperform on Vacasa, Maintains $3 Price Target
JMP Securities analyst Eric Ross reiterates Vacasa (NASDAQ:VCSA) with a Market Outperform and maintains $3 price target.
JMP Securities Reiterates Market Outperform on Inspired Entertainment, Maintains $18 Price Target
JMP Securities analyst Jordan Bender reiterates Inspired Entertainment (NASDAQ:INSE) with a Market Outperform and maintains $18 price target.
JMP Securities Reiterates Market Outperform on Booking Holdings, Maintains $2750 Price Target
JMP Securities analyst Nicholas Jones reiterates Booking Holdings (NASDAQ:BKNG) with a Market Outperform and maintains $2750 price target.
HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $7 price target.
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $15 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $15 price target.